Avstera Therapeutics Corp.
Charles "Chip" Bernhardt serves as Controller at Avstera Therapeutics Corp. since January 2022, overseeing the implementation of the CEO and Board's goals, cash flow management, and comprehensive accounting functions. Concurrently, since 2020, Bernhardt has held the position of Controller at Advaite Inc., managing various accounting activities and producing financial reports while ensuring compliance with tax and regulatory requirements. Previous roles include Interim Chief Financial Officer & Controller at SAK Fiscal Services, and Chief Financial Officer at Active Day, where strategic partnerships and financial analysis were crucial. Additional experience includes leadership positions at Echo Therapeutics, AIM ImmunoTech, Thomson Reuters, and TelAmerica Media. Bernhardt holds a Bachelor’s Degree in Accounting from Villanova University and an MBA in Business Administration from West Chester University of Pennsylvania.
This person is not in any teams
Avstera Therapeutics Corp.
Specialty oncology-focused biopharmaceutical company based in Malvern, PA with a broad pipeline encompassing novel best in class selective HDAC6i immunomodulators and a game changing myeloid based discovery platform. Avstera focuses on foundational tumor biology science, while methodologically breaking barriers using cutting-edge approaches in order to deliver impactful treatments to cancer patients.